Pleuropericardial effusion associated with minoxidil administration

D. B. WEBB
M.R.C.P. (U.K.)

R. J. WHALE*
B.Sc., M.R.C.P. (U.K.)

Department of Renal Medicine, K.R.U.F. Institute, Royal Infirmary, Newport Road, Cardiff

Summary
A patient on minoxidil developed pericardial and pleural effusions with a high protein content. This finding is not compatible with the view that such effusions in patients taking minoxidil are transudates.

Introduction
Minoxidil is a powerful vasodilator hypotensive drug which has been used extensively to control blood pressure in patients with renal failure.

Pericardial effusions are associated with minoxidil therapy (Marquez-Julio and Uldall, 1977). In cases where the protein content of the effusion has been examined in patients—some on dialysis—(Martin, Spodick and Zins, 1980; Houston, McChesney and Chatterjee, 1981) it has usually been in excess of 3 g/dl although the effusion has often been attributed to the haemodynamic effect of the drug and its tendency to cause fluid retention. The patient reported here developed a pericardial effusion with a high protein content and also pleural effusions. It is suggested that mechanisms other than fluid overload and uraemia may have a role in minoxidil related effusions.

Case report
The patient was a 43-year-old Caucasian male whose hypertension had been noted 2 years previously when he complained of bilateral, intermittent claudication. Treatment with methyldopa, atenolol and furosemide had failed to reduce his supine blood pressure below 240/130 mmHg despite compliance with therapy.

Stenosis of the left renal artery was visualized both angiographically and during aortic endarterectomy undertaken to relieve the claudication. It was not possible to correct the renal artery stenosis surgically. Isotope renography carried out when he first presented showed mild impairment of left kidney function. However considerable deterioration in left kidney function was shown on repeat renogram after 18 months.

Because of failure to control the blood pressure and the patient's intolerance of hydralazine, minoxidil was commenced at an initial dose of 5 mg twice daily on 6 July, 1980. Creatinine clearance was 35 ml/min. The minoxidil dose was subsequently increased to 10 mg twice daily with a reduction in supine blood pressure to 200/120 mmHg. At this time the chest X-ray was within normal limits and retinal examination showed grade II hypertensive retinopathy.

At review on 8 September 1980, the supine blood pressure was 230/130 mmHg and the patient was complaining of nocturnal dyspnoea. Examination showed fresh retinal haemorrhages, moderate ankle swelling and fine inspiratory crepitations at the lung bases. The jugular venous pressure was elevated to 8 cm above the sternal angle and did not vary with respiration. Chest X-ray and echocardiography confirmed a large pericardial effusion and small bilateral pleural effusions. A diagnostic pleural tap was performed and the pericardial sac was also drained of 500 ml of straw coloured fluid. The pericardial source of the fluid was confirmed by insufflation of 5 ml of air.

Both pleural and pericardial effusions had a protein content of 43 g/l. Neither contained malignant cells nor acid fast bacilli and both were sterile on culture. Antimitochondrial, smooth muscle and antinuclear antibodies were absent in both effusions and serum. The serum DNA binding was found to be within normal limits.

His acetylator status was normal and his HLA group was A2 A3 B8 B27.

The peripheral plasma renin level at the time of minoxidil administration was 5 ng/ml/hr (normal range 0.2–1.0). Despite therapy with furosemide 500 mg daily the total exchangeable body sodium was 3227 mmol (predicted 2870 mmol).

Withdrawal of the minoxidil resulted in a rise in the blood pressure and minoxidil was restarted on the basis of reported evidence that pericardial effusions recur in only a few patients following recom-
mencement of minoxidil. On this occasion recurrence did occur but resolution followed withdrawal of the drug. The blood pressure has subsequently been controlled with captopril 150 mg three times daily, atenolol 200 mg daily, hydralazine 50 mg four times daily and frusemide 500 mg daily.

Discussion
The occurrence of pericardial effusions in minoxidil-treated patients has been ascribed to the uraemia and the salt and water retention consequent on the vasodilatation produced by this drug. This patient had a minor degree of salt and water retention and the effusions contained 43 g/l of protein when the serum albumin was 31 g/l and his creatinine clearance 35 ml/min. It is therefore unlikely that the effusions were due to fluid overload alone and the relatively preserved renal function suggests that this patient does not fall into previously published groups. It is perhaps noteworthy that his HLA typing includes B8 and B27 both of which are associated with autoimmune disease although the DNA binding was normal and no antinuclear antibodies were detected.

We do not believe that previous explanations for minoxidil-induced effusions in terms of salt and water retention or renal failure fully account for the clinical and laboratory findings in this patient.

Acknowledgment
We wish to thank Professor A. W. Asscher for permission to report this case.

References
Pleuropericardial effusion associated with minoxidil administration
D. B. Webb and R. J. Whale

Postgrad Med J 1982 58: 319-320
doi: 10.1136/pgmj.58.679.319

Updated information and services can be found at:
http://pmj.bmj.com/content/58/679/319

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/